ArticleEuropean biophysics journal : EBJ2026
Homologous series of N-acylmelatonins: synthesis, biophysical studies, enhanced antioxidant, antimicrobial and anticancer activities.
Article in European biophysics journal : EBJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
N-acylmelatonins (NAMs), a class of fatty acid amides featuring melatonin as the polar head group, demonstrate significant biomedical potential. In this study, a homologous series of saturated NAMs (n = 9-18) were synthesized and fully characterized via FTIR, NMR and HRMS. The biophysical self-assembly behaviour was assessed by powder X-ray diffraction and fluorescence spectroscopy. The d-spacing determined from PXRD increases linearly with an increment of ~ 0.90 Å per CH₂ group, suggesting that the NAMs adopt a tilted bilayer structure. Fluorescence spectroscopy was employed to measure the critical micellar concentrations (CMCs) of NAMs by monitoring the spectral changes of 8-anilinonaphthalene-1-sulfonate (ANS). Fluorescence emission and lifetime measurements of NAMs show a red-shift (~ 10 nm) in emission maxima and a 2.4-fold emission intensity enhancement due to the hydrophobic acyl chain. Antioxidant properties, determined by DPPH radical scavenging assays, increased with concentration, showcasing potent activity. Notably, NAMs exhibited enhanced antimicrobial efficacy against clinically relevant bacterial and fungal strains, with minimum inhibitory concentrations comparable to standard drugs. In vitro anticancer screening revealed significant cytotoxicity against multiple human cancer cell lines, particularly with medium-chain NAMs. These findings highlight the broad-spectrum therapeutic potential of NAMs, driven by variable acyl chain length, self-assembly characteristics and strong biological applications.
Indexed as
Identifiers
42207270What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.